These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19120529)

  • 1. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
    Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
    Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Potters L; Calugaru E; Jassal A; Presser J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
    D'Souza WD; Thames HD; Kuban DA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
    Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
    Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
    Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
    Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose regions versus likelihood of cure after prostate brachytherapy.
    Wallner K; Merrick G; Sutlief S; True L; Butler W
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):170-4. PubMed ID: 15850918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
    Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
    Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.